Timber Pharmaceuticals, Inc. stock is down -81.24% since 30 days ago. The next earnings date is Dec 12, 2023. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 20% of the previous 10 November’s closed higher than October.
Timber Pharmaceuticals LLC engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders. BPX-01 is in Phase 3 topical minocycline for the. treatment of inflammatory lesions of acne vulgaris.